Fundraising FoxSofinnova Partners — 2026 Investments
5 investments dated 2026 · listed companies and verified rows first · show all
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSanofi VenturesVIVES PartnersApollo Health VenturesSixty Degree Capital
Ingenix builds an AI "Reasoning Engine" using an approach it calls Modality Fusion to integrate biological data across modalities and scales.
AI & Machine LearningBiotechDeep Tech
Adam Dancewicz(Founder)
Co-investorsInovo VCOTB Ventures
Neurent Medical develops the NEUROMARK system, a radiofrequency ablation device that targets hyperactive autonomic nerves to treat chronic rhinitis symptoms in ENT patients.
HardwareHealthtechMedical Devices
Co-investorsAtlantic Bridge VenturesClaret Capital PartnersFountain Healthcare PartnersMVM Life Science PartnersEnterprise IrelandEQT Life Sciences+1 more
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye.
BiotechDigital HealthHealthtechLongevityMedical DevicesWarren, US
HENRIC BJARKE(Chief Executive Officer)in
Co-investorsAdBio partnersF-Prime CapitalQiming Venture Partners USAQiming Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.